Literature DB >> 23357493

Chemoembolization and radioembolization for hepatocellular carcinoma.

Riad Salem1, Robert J Lewandowski.   

Abstract

Hepatocellular carcinoma (HCC) continues to represent a major worldwide problem. Although treatments such as resection, transplantation, and ablation may provide a chance for a cure, these options are often precluded because of advanced disease presentation. Palliative treatments include transarterial embolization and systemic therapies. This review will summarize the state of the science for embolic therapies in HCC (conventional and drug-eluting chemoembolization, radioembolization) as well as discuss related topics including HCC staging, assessment of response, and ongoing clinical trials.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2013        PMID： 23357493      PMCID： PMC3800021          DOI： 10.1016/j.cgh.2012.12.039

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


  59 in total

1.  Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients.

Authors:  Katerina Malagari; Mary Pomoni; Themistoklis N Spyridopoulos; Hippokratis Moschouris; Alexis Kelekis; Spyros Dourakis; Efthymia Alexopoulou; John Koskinas; Michalis Angelopoulos; John Kornezos; Anastasia Pomoni; Savvas Tandeles; Athanasios Marinis; Spyros Rizos; Dimitrios Kelekis
Journal:  Cardiovasc Intervent Radiol       Date:  2010-12-24       Impact factor: 2.740

2.  Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria.

Authors:  Daniel B Brown; Jennifer E Gould; Debra A Gervais; S Nahum Goldberg; Ravi Murthy; Steven F Millward; William S Rilling; Jean-Francois S Geschwind; Riad Salem; Suresh Vedantham; John F Cardella; Michael C Soulen
Journal:  J Vasc Interv Radiol       Date:  2009-07       Impact factor: 3.464

3.  Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial.

Authors:  Thomas J Vogl; Johannes Lammer; Riccardo Lencioni; Katerina Malagari; Anthony Watkinson; Frank Pilleul; Alban Denys; Clara Lee
Journal:  AJR Am J Roentgenol       Date:  2011-10       Impact factor: 3.959

4.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

5.  Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation.

Authors:  Ahsun Riaz; Khairuddin Memon; Frank H Miller; Paul Nikolaidis; Laura M Kulik; Robert J Lewandowski; Robert K Ryu; Kent T Sato; Vanessa L Gates; Mary F Mulcahy; Talia Baker; Ed Wang; Ramona Gupta; Ritu Nayar; Al B Benson; Michael Abecassis; Reed Omary; Riad Salem
Journal:  J Hepatol       Date:  2010-10-23       Impact factor: 25.083

6.  Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.

Authors:  Katerina Malagari; Mary Pomoni; Alexis Kelekis; Anastasia Pomoni; Spyros Dourakis; Themis Spyridopoulos; Hippokratis Moschouris; Emmanouil Emmanouil; Spyros Rizos; Dimitrios Kelekis
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-24       Impact factor: 2.740

7.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.

Authors:  Laura M Kulik; Brian I Carr; Mary F Mulcahy; Robert J Lewandowski; Bassel Atassi; Robert K Ryu; Kent T Sato; Al Benson; Albert A Nemcek; Vanessa L Gates; Michael Abecassis; Reed A Omary; Riad Salem
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

8.  Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation.

Authors:  M Victoria Gonzalez; Yiqing Tang; Gary J Phillips; Andrew W Lloyd; Brenda Hall; Peter W Stratford; Andrew L Lewis
Journal:  J Mater Sci Mater Med       Date:  2007-07-25       Impact factor: 3.896

9.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Authors:  Alejandro Forner; Carmen Ayuso; María Varela; Jordi Rimola; Amelia J Hessheimer; Carlos Rodriguez de Lope; María Reig; Luís Bianchi; Josep M Llovet; Jordi Bruix
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

10.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740
View more
  24 in total

Review 1.  Advances in Biomaterials and Technologies for Vascular Embolization.

Authors:  Jingjie Hu; Hassan Albadawi; Brian W Chong; Amy R Deipolyi; Rahul A Sheth; Ali Khademhosseini; Rahmi Oklu
Journal:  Adv Mater       Date:  2019-06-06       Impact factor: 30.849

Review 2.  Radioembolization for hepatocellular carcinoma: current role and future directions - the medical oncologist's perspective.

Authors:  Peter Gibbs; Jeanne Tie; Lourens Bester
Journal:  Hepat Oncol       Date:  2015-04-20

Review 3.  Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts.

Authors:  Christopher Molvar; Robert Lewandowski
Journal:  Semin Intervent Radiol       Date:  2015-12       Impact factor: 1.513

Review 4.  [Hepatocellular carcinoma].

Authors:  C Czauderna; J U Marquardt; P R Galle; M A Wörns
Journal:  Internist (Berl)       Date:  2017-05       Impact factor: 0.743

Review 5.  [Primary liver tumors. Preoperative conditioning of the liver and perioperative management in extended liver resection].

Authors:  S Heinrich; H Lang
Journal:  Chirurg       Date:  2015-02       Impact factor: 0.955

Review 6.  Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.

Authors:  Do Young Kim; Kwang-Hyub Han
Journal:  Hepatol Int       Date:  2016-04-28       Impact factor: 6.047

7.  Development of biodegradable radiopaque microsphere for arterial embolization-a pig study.

Authors:  Yi-Sheng Liu; Xi-Zhang Lin; Hong-Ming Tsai; Hung-Wen Tsai; Guan-Cheng Chen; Syuan-Fong Chen; Jui-Wen Kang; Chen-Miao Chou; Chiung-Yu Chen
Journal:  World J Radiol       Date:  2015-08-28

8.  Biodistribution, Pharmacokinetics and Efficacy of 188Re(I)-Tricarbonyl-Labeled Human Serum Albumin Microspheres in an Orthotopic Hepatoma Rat Model.

Authors:  Liang-Cheng Chen; Wan-Chi Lee; Chung-Li Ho; Ya-Jen Chang; Su-Jung Chen; Chih-Hsien Chang
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

9.  Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study.

Authors:  Parvez S Mantry; Ashwini Mehta; Bahar Madani; Alejandro Mejia; Islam Shahin
Journal:  J Gastrointest Oncol       Date:  2017-10

Review 10.  Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

Authors:  Josep M Llovet; Thierry De Baere; Laura Kulik; Philipp K Haber; Tim F Greten; Tim Meyer; Riccardo Lencioni
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-01-28       Impact factor: 46.802
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.